Tricuspid Valve

This channel is dedicated to news and trends in tricuspid valve interventions, surgical and transcatheter, to manage regurgitation and valve stenosis. The tricuspid valve is a rapidly growing area in structural heart interventions. Minimally invasive transcatheter tricuspid valve replacement (TTVR) and repair using transcatheter edge to edge repair (TEER) clips are expected to become a new standard of care in the next couple years, partly because open heart tricuspid surgery has historically has poor outcomes.

RSS icon
Abbott TriClip device for TEER

TriClip triumphs: Tricuspid edge-to-edge repair linked to strong 30-day outcomes in real-world setting

The new study, published in the Journal of the American College of Cardiology, focused on more than 500 patients treated with Abbott’s TriClip device in Europe.

TricValve Transcatheter Bicaval Valves System and HeartMate II LVAD

Cardiologists shed new light on treating severe tricuspid regurgitation in high-risk heart failure patients

The 80-year-old patient was experiencing severe TR and already had a HeartMate II LVAD. 

The LuX-Valve Plus transcatheter tricuspid valve replacement (TTVR) device

Cardiologists make history, perform TTVR with new-look valve for first time in U.S.

The new valve was placed inside the damaged valve via a catheter that is inserted through a small incision in the patient's neck. 

Paul Sorajja, MD, director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, Abbott Northwestern Hospital, was the principal investigator for the late-breaking TRILUMINATE pivotal trial at the American College of Cardiology (ACC) 2023 meeting and explains details of this landmark trial. #ACC #ACC23 #triluminate

TRILUMINATE trial may pave the way for FDA clearance for tricuspid valve clip device

Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

ACC.23 Together with the World Congress of Cardiology

Day 1 at ACC.23 features late-breaking studies on bempedoic acid, tricuspid valve repair and statins

The conference kicked off with three late-breaking studies that could have a huge impact on patient care going forward. 

Edwards Lifesciences Corporation has shared new one-year data on the safety and effectiveness of its Evoque transcatheter tricuspid valve replacement (TTVR) system among patients with tricuspid regurgitation (TR)

Edwards shares new one-year data on transcatheter tricuspid valve replacement

The new findings, presented at the PCR London Valves 2022 conference, focused on mortality and heart failure hospitalization rates. 

Mitral and_tricuspid transcatheter valves Evoque and Intrepid were discussed at TVT 2022.

VIDEO: Advances in transcatheter tricuspid and mitral valve technology

Anita W. Asgar, MD, director, transcatheter valve therapy research at Montréal Heart Institute, discusses advances and new technology for mitral and tricuspid valves at the 2022 Transcatheter Valve Therapies (TVT) meeting. 

Adam Greenbaum, MD, Emory, explains the CLASP TR trial of the Pascal clip device for transcatheter repair, which was a late-breaking ACC22 study.

VIDEO: Pascal effective in transcatheter repair of tricuspid valve regurgitation

Adam Greenbaum, MD, co-director of the Structural Heart and Valve Center at Emory University Hospital Midtown in Atlanta, explains details from the late-breaking CLASP TR trial at ACC.22.

Displaying 33 - 40 of 46
Design by Adaptive Theme